The ongoing controlled clinical trials are expected to address the major questions concerning the indications and benefits of autologous HSCT in ADs, enabling the referral for transplantation patients with a favorable risk–benefit profile in each setting of AD. Autologous HSCT has been explored in ADs as a means of overcoming autoimmunity through a reconditioning of the immune system. In the field of cellular therapy, mesenchymal cell transplantation, bearing the potential of switching off autoimmunity, might become an effective alternative to autologous HSCT, notably in the varieties of ADs deriving a limited benefit, if any, from HSCT.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript
Expert Rev Hematol. 2009;2(6):699-715. © 2009 Expert Reviews Ltd.
Cite this: Autologous Hematopoietic Stem Cell Transplantation in Autoimmune Diseases - Medscape - Dec 01, 2009.